Overview
On 14 October 2016, orphan designation (EU/3/16/1742) was granted by the European Commission to Therapicon Srl, Italy, for acebutolol hydrochloride for the treatment of Smith-Magenis syndrome.
The sponsorship was transferred to Worphmed S.r.l., Italy in March 2019.
Key facts
Active substance |
Acebutolol hydrochloride
|
Intended use |
Treatment of Smith-Magenis syndrome
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/16/1742
|
Date of designation |
14/10/2016
|
Sponsor |
Worphmed S.r.l. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: